Last updated on November 2018

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Brief description of study

The 12-week, phase 2 study is intended to evaluate the safety and efficacy of IDP-126 Gel, a novel fixed-dose combination of clindamycin phosphate, benzoyl peroxide and adapalene relative to placebo and dual component combinations for the treatment of acne vulgaris in subjects 9 years of age and older. All subjects will receive once daily, topically-applied treatment to the face for 12 weeks.  Subjects will apply their treatments at home, once daily in the evening. There are 6 in-office visits throughout the 12 weeks of the study and can include a physical exam, blood draws, urine sampling, assessments by qualified professionals and other assessments which will be reviewed in detail at your screening visit. All services are provided at no cost.

Clinical Study Identifier: TX205368

Find a site near you

Start Over

Sadick Research Group

911 Park Avenue, Ste. 1A New York, NY United States
  Connect »